Abstract
SUMMARY Late Volumetric Analysis After Implantation ofSirolimus- Versus Biolimus A9-eluting Stents Introduction: Sirolimus-eluting stents (SES) significantly re-duce restenosis and major adverse cardiac events (MACE)compared to bare metal stents (BMS). The novel sirolimusanalog, Biolimus A9T (BA9), presented similar safety andefficacy in the randomized, controlled STEALTH I trial.This study compared the efficacy of a BA9-eluting stentversus sirolimus-eluting and bare metal control stents. Me-thods: Forty-five patients with de novo coronary lesionswere randomly assigned in a 2:1 basis to receive eitherBA9-eluting (n = 30) or bare metal (n=15) S-stents. Quan-titative coronary angiography (QCA) and intravascularultrasound (IVUS), at 6 months, were then compared to amatched series of patients who received either sirolimus-eluting (n = 30) or bare metal (n = 15) Bx Velocity stents.Baseline clinical and angiographic characteristics weresimilar among all groups, except for a significantly higherpercentage of females and Class C lesions in the BA9-eluting stent group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
